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Like most other lentiviruses, maedi-visna virus (MVV) requires Vif for replication in natural target cells
and in vivo. Here, we show that Vif-deﬁcient MVV accumulates G–A mutations in the sequence context
characteristic of ovine APOBEC3, consistent with a role of MVV Vif in neutralizing APOBEC3. We studied
two point mutations in the vif gene of MVV. One was a tryptophan to arginine mutation that affects the
interaction with APOBEC3 and caused G–A hypermutation. The other mutation was a proline to serine
mutation that together with a mutation in the capsid protein caused attenuated replication in fetal ovine
synovial (FOS) cells but not in sheep choroid plexus (SCP) cells. There was no hypermutation associated
with this mutation. These results suggest that MVV Vif exerts more than one function and that there may
be interaction between Vif and the capsid. The results also suggest the involvement of an unknown host
factor in MVV Vif function.
& 2015 Elsevier Inc. All rights reserved.Introduction
Maedi-visna virus (MVV) is a lentivirus of sheep, mainly
affecting the lungs and the nervous system. The target cells of
MVV infection are predominantly cells of the monocyte/macro-
phage lineage, and virus expression is activated upon macrophage
maturation (Gorrell et al., 1992; Petursson et al., 1991). Like other
lentiviruses except equine infectious anemia virus (EIAV), MVV
requires Vif (virion infectivity factor) for efﬁcient replication in
primary macrophages and in vivo (Kristbjornsdottir et al., 2004).
Human immunodeﬁciency virus type 1 (HIV-1) Vif has been
shown to neutralize human APOBEC3 (hA3) proteins, which are
cellular inhibitors of HIV-1 replication. The hA3 proteins are
cytosine deaminases that deaminate C to U within newly syn-
thesized single-strand DNA of the virus, leading to G–A mutation
in the proviral DNA or degradation of the retroviral cDNA prior to
integration (Harris et al., 2003; Lecossier et al., 2003; Sheehy et al.,
2002). There is also evidence to suggest that some of the hA3
proteins can inhibit virus replication in the absence of hypermu-
tation (Holmes et al., 2007; Newman et al., 2005).hology, University of Iceland,Whereas the primates have seven A3 genes, sheep and cattle
have three and mice have only one (Harris and Liddament, 2004;
Jonsson et al., 2006; LaRue et al., 2008; OhAinle et al., 2006). Sheep
code for at least four A3 proteins from three genes; OaA3Z1,
OaA3Z2 and OaA3Z3, and a double domain protein, OaA3Z2-Z3. All
four proteins elicit DNA cytosine deaminase activity. The double
domain protein OaA3Z2-Z3 has a similar subcellular distribution
as A3F and A3G in humans and it is neutralized by MVV Vif. It has
a preference for deaminating cytosines in the sequence context T
(T/C)C, which we show here is the target site for mutations in Vif-
deﬁcient (dVif) strains. OaA3Z2-Z3 is therefore likely to be the
predominant antiretroviral ovine A3 in vivo (Jonsson et al., 2006;
LaRue et al., 2008). The A3 proteins have very broad antiviral
activity, thus A3s of mice, sheep, pigs and cows as well as those of
primates can inhibit HIV-1 (Bishop et al., 2004; Jonsson et al.,
2006). Vif function, however, is highly host-speciﬁc. For instance,
Vif of HIV-1 can neutralize many of the human A3s, but not those
of African green monkey, mice, sheep, pigs or cows, and the Vif
proteins of MVV, BIV and FIV could not restore replication of dVif
HIV-1 in human cells (Jonsson et al., 2006; Mariani et al., 2003;
Simon et al., 1995). However, recent studies have shown that some
Vif-A3 interactions are more promiscuous than previously appre-
ciated. Thus, MVV Vif not only leads to degradation of ovine A3,
but also human and rhesus macaque A3H as well as cat and cow
Z3 type A3 proteins. (Larue et al., 2010).
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somal degradation by recruiting cullin5-ElonginB/C through a viral
speciﬁc BC-box ( SLQXLA) and a novel HCCH zinc binding motif and
thereby preventing encapsidation of the hA3G and hA3F proteins
(Luo et al., 2005; Yu et al., 2003). The recruitment of the non-
canonical cofactor core-binding factor beta (CBFβ) is also required for
HIV-1 Vif A3 degradation activity in vivo (Jager et al., 2012). Several
amino acids in the N-terminal part of HIV-1 Vif have been shown to
be important in the interaction between Vif and A3 proteins (Mehle
et al., 2007; Russell and Pathak, 2007; Tian et al., 2006).
The MVV vif gene encodes a 29 kDa highly basic protein that is
expressed in the late phase along with the structural proteins
(Audoly et al., 1992). Despite limited amino acid similarity, all Vif
proteins contain the BC-box, SLQXLA (Oberste and Gonda, 1992;
Yu et al., 2003). CBFβ, which is required for HIV-1 Vif A3 degra-
dation activity in vivo is completely dispensable for MVV Vif
function, but MVV Vif uniquely requires a novel cofactor, cyclo-
philin A (CYPA) for anti-A3 activity (Kane et al., 2015). It therefore
appears that the lentivirus vif genes have evolved differently to
neutralize their respective host A3 proteins.
Retrovirus capsids have been shown to be targets for host
restriction in a number of cell–virus systems. TRIM5α, a protein
that belongs to a family of around 70 so-called tripartite motif
(TRIM)-containing proteins, has been shown to be responsible for
most of this restriction. Recently, an active TRIM5α protein was
identiﬁed in ovine cells (Jauregui et al., 2012).
In a previous study we identiﬁed a point mutation in the vif
gene of MVV, that together with a mutation in CA rendered the
virus replication defective both in vitro and in vivo (Gudmundsson
et al., 2005). This mutant (CA(L120R)-Vif(P205S)) had different
replication properties in vitro to a Vif-deleted MVV (dVif), in that
CA(L120R)-Vif(P205S) was replication proﬁcient in sheep choroid
plexus (SCP) cells, whereas the dVif MVV was not. Neither virus
could replicate in macrophages or was infectious in vivo. In the
present study, we constructed a tryptophan to arginine substitu-
tion (W98R) in the central part of Vif to further elucidate the
function of Vif. We tested the replication proﬁciency of mutant
viruses with this mutation in a wild type background and together
with the CA (L120R) mutation, and compared to the Vif(P205S)
mutation both in wild type and a CA(L120R) background. The virus
with the Vif(W98R) mutation replicated poorly in SCP cells
whereas fetal ovine synovial (FOS) cells were semi-permissive. An
increased frequency of G–A mutations was detected in SCP derived
viral genomes. The context of these mutations matches the target
sequence of ovine A3Z2-Z3 (Jonsson et al., 2006), indicating that
this residue was associated with ovine A3Z2-Z3 neutralization.
This phenotype was identical in both a wild type and a CA(L120R)
background. The Vif (P205S) mutation, however, did not cause G–A
mutations in the nonpermissive (FOS) cells. These results suggest
that MVV Vif has at least two functions; A3 antagonism, and an
additional function which is associated with the capsid and
dependent on an unknown cell-speciﬁc host factor.Results
Two mutations in the vif gene result in different replication properties
We have previously shown that a P205S mutation in the
C-terminus of Vif has a different phenotype than dVif. The Vif
(P205S) mutation does not have a detectable effect on replicationMVV Vif
W98R1
Fig. 1. A schematic of MVV Vif. The conserved BC-box SLQRLA is shaon its own, but in combination with a mutation in the capsid, CA
(L120R), there is markedly reduced replication proﬁciency in fetal
ovine synovial (FOS) cells, macrophages and in vivo, while SCP cells
are fully permissive (Gudmundsson et al., 2005; Kristbjornsdottir
et al., 2004). The main goal of this study was to present evidence
for two distinct functions of Vif by introducing point mutations
into different parts of the protein and characterizing the resulting
phenotypes. To this end, we introduced a W98R substitution in Vif,
using the MVV molecular clone KV1772 as a backbone, with or
without the CA(L120R) mutation. This mutation in Vif was selected
since it had been previously shown to attenuate the replication of
the closely related caprine arthritis encephalitis virus (CAEV)
(Seroude et al., 2001) and we found that it was unable to restrict
the activity of OaAZ2-Z3 using HEK293T cells. The locations of the
two introduced mutations in Vif are shown in Fig. 1. The recom-
binant viruses were tested for replication in FOS cells and SCP
cells. Cells were infected with equal amounts of virus (as deter-
mined by measuring RT activity) and viral replication was mon-
itored daily by using a TaqMan-based real-time RT-PCR assay. The
Vif(P205S) mutation had little effect in the KV1772 background,
whereas the Vif(W98R) displayed slower replication kinetics and
replicated to lower titers in SCP cells as compared to the wild-type
KV1772 strain. A dVif mutant with most of the vif gene deleted was
included for comparison, and the replication kinetics of the Vif
(W98R) mutant were similar to the dVif mutant. The FOS cells were
somewhat more permissive both for dVif and the Vif(W98R)
mutant (Fig. 2A and B). In the background of the CA(L120R)
mutation, however, the replication efﬁciency of the virus with the
Vif(W98R) mutation was similar to the KV1772 background both in
SCP and in FOS cells, while virus with the Vif(P205S) mutation in a
CA(L120R) background replicated distinctively slower and to a
lower titer in FOS cells than in SCP cells (Fig. 2C and D). It therefore
appears that the attenuated replication of the CA(L120R)-Vif(P205S)
mutant in FOS cells is not an additive effect of two unrelated
mutations but rather suggests that the mutations disrupt some
interaction of CA and Vif.
The Vif(P205S) mutation deﬁnes a function of Vif different from A3
neutralization
To address the question whether the CA(L120R)-Vif(P205S) inter-
action was in any way related to the known role of Vif in counter-
acting A3, we analyzed the putative effect of A3 editing on the
virions with different mutations in vif. For mutational analysis, we
sequenced a 428 bp region in the env gene of individual viral
genomes (nt 6947–7323 in the molecular clone KV1772 (Andresson
et al., 1993)). As shown in Fig. 3, a high number of G–A mutations
was observed in dVif virions produced in SCP cells. The same was
true for the Vif(W98R) mutant. The preferred sequence context for
the G–A mutations is shown in Fig. 3. Seventy-eight per cent of the
G–A mutations in the dVif strain and 70% G–A mutations in the Vif
(W98R) mutant occurred in G(G/A)A trinucleotides. This is in
accordance with the preferred sequence context of OaA3Z2–Z3
editing (Jonsson et al., 2006; LaRue et al., 2009) and indicates that
these mutations in the vif gene disrupt the ability of Vif to neu-
tralize OaA3Z2-Z3. However, no G–A hypermutation was found in
the CA(L120R)-Vif(P205S) proviruses, neither produced in SCP cells
(data not shown) nor in the non-permissive FOS cells (Fig. 3).
To further determine A3 degradation induced by the different
mutated Vifs, HEK293T cells were co-transfected with OaA3Z2-Z3-
HA and either wtVif-HA, Vif(SLQ-AAA)-HA, Vif(P205S)-HA or VifP205S173SLQRLA 230
ded and the positions of the two point mutations are indicated.
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Fig. 2. Replication kinetics of virus production in SCP cells (A and C) and FOS cells (B and D) as measured by TaqMan-based RT-qPCR.
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Fig. 3. Hypermutation assay of wt MVV and vif mutants. (A) A histogram depicting the frequencies of G–A mutations observed in MVV clones after infection of non-
permissive cells; SCP cells for KV1772wt, dVif, and VifW98R, and FOS cells for CA(L120R)-Vif(P205S). 12–19 clones were sequenced for each virus. Infected cells were taken from
the spreading infection shown in Fig. 2. (B) Trinucleotide context of the mutations in (A).
S.R. Franzdóttir et al. / Virology 488 (2016) 37–42 39(W98R)-HA. Vif with the P205S mutation degraded A3 as efﬁciently
as wild type Vif, while Vif(W98R) and Vif(SLQ-AAA) were unable to
degrade A3 (Fig. 4). The Vif(P205S) mutation therefore appears to
deﬁne a function of Vif different from A3 degradation.OaA3Z2-Z3-HA
Vif-HA
β-acn
Fig. 4. OaA3Z2-Z3 degradation activity of wt and mutated Vif. Cells were tran-
siently transfected with HA-tagged OaA3Z2-Z3 and either wt or mutated Vif.Discussion
The role of the Vif protein of HIV-1 in counteracting the anti-
viral activity of hA3G and hA3F has been extensively studied
S.R. Franzdóttir et al. / Virology 488 (2016) 37–4240(reviewed in (Henriet et al., 2009; Wissing et al., 2010). Our
ﬁndings that vif-deﬁcient MVV accumulates G–A mutations with
an OaA3Z2-Z3-like trinucleotide mutation spectrum suggest that
OaA3Z2-Z3 is active in vivo. The sequence context preferred by the
OaA3Z2-Z3 is T(C/T)C in the minus strand which translates to G(A/
G)A in the plus-strand DNA. This target sequence resembles that
for the murine A3 (Esnault et al., 2005) more than any of the
human A3 proteins which may reﬂect the dynamic evolution of
the A3 genes in primates (Jonsson et al., 2006; LaRue et al., 2008).
In this study we described the different phenotypes of two
point mutations in Vif, one was a W98R mutation and the other
was a P205S mutation. A Vif P205S mutant replicated well in SCP
and FOS cells; however, when in combination with a L120R
mutation in the capsid, the virus displayed a conditionally syn-
thetically deleterious phenotype, with the virus replicating well in
SCP cells, but undergoing distinctively retarded replication in FOS
cells. A Vif(W98R) mutant showed a slower rate of replication in
SCP cells as well as FOS cells, and there was no effect of the
mutation in the capsid.
The W98 residue in Vif was originally described in CAEV Vif as
necessary for efﬁcient virus replication and unrelated to Gag
binding (Seroude et al., 2001). The G–A hypermutation in the
target sequence G(A/G)A associated with this mutation in addition
to the inability to degrade OaA3Z2-Z3 in vitro (Fig. 4) indicates
that the mutation disrupts Vif-mediated degradation of OaA3Z2-
Z3. This is consistent with the ﬁnding in HIV-1 Vif that most of the
highly conserved Trp residues in the N-terminal end of Vif are
involved in A3 binding (Tian et al., 2006).
The P205S mutation is in the C-terminal part of Vif where
membrane association, Vif multimerization and interaction with
the nucleocapsid part of Gag have been mapped for HIV-1 (Bouyac
et al., 1997; Goncalves et al., 1994; Goncalves et al., 1995; Jonsson
et al., 2006; Yang et al., 2001). Interaction of Vif with the NC part of
Gag has also been mapped in this region in CAEV (Seroude et al.,
2001). There was no G–A hypermutation associated with this
mutation and the mutation did not affect the ability of Vif to
degrade OaA3Z2-Z3.
When the CA(L120R)-Vif(P205S) mutant was ﬁrst described
(Gudmundsson et al., 2005), there was some concern that the two
mutations were unrelated and that the effect was additive. In this
study we show that the mutation in CA has no detectable effect on
a point mutation that affects A3 interaction of Vif (Vif(W98R)),
neither in SCP nor FOS cells, whereas it has a profound effect on
Vif(P205S) replication in FOS cells (Fig. 2).
Our hypothesis is that there exists some restrictive activity in
FOS cells that is not present in SCP cells. The CA(L120R)-Vif(P205S)
mutant may either be unable to evade detection by this activity or
is unable to antagonize it to prevent its anti-viral function.
Despite much effort, we have not been able to show any
interaction between Vif and CA, and neither have others (Seroude
et al., 2001). The mutation in the capsid is an L-to-R mutation in
amino acid 120 of the capsid corresponding to K131 in helix 7 in
the HIV-1 CA. There is a charged amino acid in this position in all
lentiviral capsids except those of MVV and CAEV (von Schwedler
et al., 1998). MVV is restricted by sheep TRIM5 when over-
expressed in cell culture (Jauregui et al., 2012) but it is not known
how MVV escapes TRIM5 in vivo. It has been reported that TRIM5
escape mutants in other retroviruses often involve charge-changes
(Ohkura and Stoye, 2013), and it could be speculated that the
capsids of MVV and CAEV have evolved to substitute L for R120 in
order to escape endogenous TRIM5. The L120R mutation would
then make the capsid sensitive to endogenous TRIM5, which Vif
would normally compensate. Cyclophilin A binds to HIV-1 capsid
and has a role in modulating TRIM5 restriction (Sokolskaja et al.,
2006), but does not bind to MVV capsid (Kane et al., 2015).
Cyclophilin A binds to MVV Vif, however, and is required for theanti-A3 function of the MVV Vif protein, but it may have another
function as well, i.e. to modulate TRIM5 restriction.
Whether cyclophilin A or some other host protein is the
missing link between Vif and the capsid, suggested by the mutant
phenotypes described here, is under investigation.Materials and methods
Construction of Vif(W98R) and CA(L120R)-Vif(W98R) MVV infectious
clones and expression plasmids
The molecularly cloned maedi-visna virus KV1772 has been
described previously (Andresson et al., 1993; Skraban et al., 1999). The
clone is contained in two plasmids, p8XSp5-RK1 and p67r (Skraban et
al., 1999). For construction of Vif(W98R), the BamHI/HincII fragment
(nucleotides 4587–6392) from p8XSp5-RK1 was cloned into pUC19.
The tryptophan to arginine substitution at position 98 of Vif was
generated by PCR-mediated site-directed mutagenesis using oligonu-
cleotides 5'- GAAATGCAAGGCAATATAAAAGCCAGGG-3' (nucleotides
5250–5276) and 5'-CCCTGGCTTTTATATTGCCTTGCATTTC-3 (nucleo-
tides 5276–5250). The resulting pUC19BamHI4587-HincII6392 plasmid
was digested with MluI and BglII and the MluI4680-BglII5841 fragment
was isolated and cloned into p8XSp5-RK1 with or without the CA-
L120R mutation for generating Vif(W98R) or CA(L120R)-Vif(W98R),
respectively. The Vif (P205S) and CA(L120R)-Vif (P205S) molecular clones
have been described previously (Gudmundsson et al., 2005).
For expression vectors, the W98R and P205S mutations were
introduced by site-directed mutagenesis into codon-optimized MVV
Vif constructs with C-terminal Myc tags in pVR1012 (Larue et al.,
2010). For the W98R mutation, the primers 5‘CGCAACGCTCGGCAG-
TACAAG 3‘ forward and 5‘CTTGTACTGCCGAGCGTTGCG3‘
reverse were used, and for the P120S mutation the primers
5‘GTGCAAAAGTTCTCATGGTGCAGG3‘ forward and 5‘CCTGCACCAT-
GAGAACTTTTGCAC3’ reverse were used.
All mutations were veriﬁed by sequencing.
Cells, virus and transfections
SCP cells (Georgsson et al., 1976; Sigurdsson et al., 1960) and
FOS cells (Andresson et al., 1993), were grown in Dulbecco's
modiﬁed Eagle medium (DMEM) supplemented with 2 mM glu-
tamine, 100 IU of penicillin per ml, 100 IU of streptomycin per ml,
and either 10% lamb serum (growth medium) or 1% lamb serum
(maintenance medium).
FOS cells were grown in 25 cm2 ﬂasks to 90–95% conﬂuency for
transfection by Lipofectamine as speciﬁed by the manufacturer
(Invitrogen). Equimolar quantities of the two plasmids containing
the viral genome, a total of 6 mg DNA, were cut with XbaI and
ligated before transfection.
Supernatants from transfected cells were passaged into SCP
cells when cytopathic effect appeared or RT was detected. Multi-
plicity of infection (moi) was calculated by the Reed-Muench
method as TCID50/ml.
RT assay
Viral particles from 300 ml of cell-free supernatants from
infected cells were pelleted at 14,000 rpm for 1 h in a microfuge.
The pelleted virus was resuspended in TNE (10 mM Tris–HCl (pH
7.5), 100mM NaCl, 1mM EDTA) containing 0.1% Triton X-100. RT
activity was assayed on a poly(A) template, adding oligo-dT primer
and dTTP. The resulting RNA–DNA heteroduplexes were detected
by PicoGreen reagent as speciﬁed by the manufacturer (Molecular
Probes Inc., Eugene, Oregon).
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Six-well plates were seeded with 5105 HEK293T cells per
well and transfected the next day using Lipofectamine LTX as
speciﬁed by the manufacturer. To assay for degradation of
OaA3Z2-Z3 by wt MVV Vif and the various mutant Vif proteins,
0.2 mg pcDNA3.1-OaA3Z2-Z3-3xHA and 0.2 mg pVR1012-Vif-3xHA
were used for cotransfection. To maintain equivalent DNA
amounts, empty pVR1012 vector DNA was used when needed.
After 48–72 h cell lysates were harvested and boiled for 5 min
before the proteins were separated by SDS-PAGE and transferred
to PVFD transfer membrane. Immunoblotting was performed with
antibodies against the HA-tag. β-actin was used as a loading
control. Secondary antibodies were HRP-conjugated anti-rabbit or
anti-mouse antibodies (Dako), and detection was carried out using
Pierce ECL Plus Western Blotting Substrate (Thermo Scientiﬁc).
Hypermutation assays
Hypermutation of the various Vif mutants was detected by
amplifying and sequencing a 428 bp fragment (nucleotides 6911–
7339) from the env gene, using proviral DNA from infected cells.
Multiple PCR reactions were performed and cloned into pUC19
plasmids. One clone from each PCR reaction was sequenced to
ensure independent sampling.
Real-time PCR assay
Viral particles from 300 ml of cell-free supernatants from infected
cells were pelleted at 14,000 rpm for 1 h in a microfuge. The pellet
was dissolved in 10 ml TNE (10 mM Tris pH 7.5; 100 mM NaCl; 1 mM
EDTA) with 0.1% Triton X-100. This lysate was used for generating
cDNA using RevertAid M-MuLV reverse transcriptase (Fermentas)
and a primer from the gag gene (V-1818 5’CGG GGTACCTTACAACA-
TAGGGGGCGCGG 3'). Real-time PCR was carried out in a ﬁnal volume
of 20 ml. The primers and Taqman probe were as follows: Forward
primer: V1636 50 -TAAATCAAAAGTGTTATA ATTGTGGGA- 30, reverse
primer: V-1719: 50-TCCCACAATGATGGCATATTA TTC- 30, Taqman
probe: V1665Taqman 50-FAM-CCAGGACATCTCGCAAGA CAGTGTA-
GACA-BHQ-1 30. Calibration curves were derived by running 10-
fold dilutions of speciﬁc cDNA over the range of 60 to 6107 copies.
Each assay included duplicate wells for each dilution of calibration
DNA and for each cDNA sample.Acknowledgments
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